2020
DOI: 10.1007/s12254-020-00571-7
View full text |Buy / Rent full text
|
Sign up to set email alerts
|

Abstract: SummaryStarting with the approval of bortezomib, a proteasome-inhibiting drug, tremendous progress has been achieved in the treatment of multiple myeloma (MM) patients during the last 15 years. Due to a plethora of novel drugs such as second generation proteasome inhibitors, immunomodulating agents and monoclonal antibodies the 5‑year survival of MM patients has been extended from 33% at the turn of the millennium to approximately 60% in younger patients (<65–70 years) who were eligible for consolidation wi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
6
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 5 publications
(6 citation statements)
references
References 42 publications
(43 reference statements)
0
6
0
Order By: Relevance
“…The underlying mechanisms for therapeutic resistance have remain largely unclear, but tumor heterogeneity, and antigen escape have been implicated 50 .…”
Section: Limitations To Bcma-car-t Therapymentioning
confidence: 99%
See 1 more Smart Citation
“…The underlying mechanisms for therapeutic resistance have remain largely unclear, but tumor heterogeneity, and antigen escape have been implicated 50 .…”
Section: Limitations To Bcma-car-t Therapymentioning
confidence: 99%
“…For BCMA antigen escape, one of the most well-described ways is the erroneous physiology of the BCMA antigen. BCMA can be inadvertently transferred from tumors to T cells in a process called trogocytosis, causing T-cell fatricide 3 , 50 or it can be shed into the blood circulation (now called serum BCMA (sBCMA)), mediated by γ-secretase 47 . Both can cause dampening of tumor cell recognition 38 , 54 .…”
Section: Limitations To Bcma-car-t Therapymentioning
confidence: 99%
“…as two likely culprits. 8,9 Understanding these potential mechanisms can aid in physicians' decisions to initiate subsequent treatment with either a regimen that re-challenges anti-BCMA therapy or one that utilizes another target entirely.…”
Section: Anti-bcma Therapy Use and Failurementioning
confidence: 99%
“…The exposure of BCMA-positive tumor cells to BCMA-directed CAR T-cells leads to selection of those tumor cells with lower expression of BCMA and therefore to resistance against CAR-T cells [66]. One of the possible explanations of BCMA antigen escape is the process called trogocytosis-BCMA can be transferred from tumors to T-cells causing T-cell fratricide [67]. Or it can be shed in the blood circulation which is mediated by -secretase [68].…”
Section: Limitations Of Car T-cell Therapymentioning
confidence: 99%